<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dronabinol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dronabinol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dronabinol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9394" href="/d/html/9394.html" rel="external">see "Dronabinol: Drug information"</a> and <a class="drug drug_patient" data-topicid="12403" href="/d/html/12403.html" rel="external">see "Dronabinol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16116938"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Marinol;</li>
<li>Syndros</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058225"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiemetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F163518"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use caution when increasing the dose of dronabinol because of the increased frequency of dose-related adverse reactions at higher dosages. Dronabinol is available in capsules and an oral solution; they are not bioequivalent and should not be used interchangeably on a mg:mg basis. Pediatric dosing is based on experience with the capsule formulation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8af8851d-d217-4c88-b8c4-e8e375e71954">Nausea and vomiting, refractory; chemotherapy-induced nausea and vomiting or palliative care</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting, refractory; chemotherapy-induced nausea and vomiting (CINV) or palliative care:</b> Limited data available: <b>Note:</b> Although use of dronabinol for refractory CINV is not described as a therapeutic option in consensus reports, it may be necessary for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12956617','lexi-content-ref-26960036','lexi-content-ref-32678694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12956617','lexi-content-ref-26960036','lexi-content-ref-32678694'])">Ref</a></span>). Initiate with the lowest recommended dose and titrate to response.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Capsules: 2.5 to 5 mg/m<sup>2</sup>/dose every 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ullrich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ullrich.1'])">Ref</a></span>); calculated dose should be rounded to the nearest 2.5 mg increment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32678694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32678694'])">Ref</a></span>). In adults, usual fixed doses are 2.5 to 10 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18391612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18391612'])">Ref</a></span>). Due to increased risk of adverse effects, some experts suggest avoiding use in children &lt;6 years and using with caution in patients 6 to 12 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Orkin.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Orkin.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094234"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51094235"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F163507"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9394" href="/d/html/9394.html" rel="external">see "Dronabinol: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use caution when increasing the dose of dronabinol because of the increased frequency of dose-related adverse reactions at higher dosages.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52a09054-c17a-4002-8ebd-6926f20d3f9e">Anorexia in patients with AIDS</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anorexia in patients with AIDS:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Initial: 2.5 mg twice daily (1 hour before lunch and dinner); for patients unable to tolerate this dosage, may reduce to 2.5 mg once daily (1 hour before dinner or at bedtime to reduce the risk of CNS symptoms). May increase dose gradually based on response and tolerability (maximum: 20 mg/day in 2 divided doses).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Initial: 2.1 mg twice daily (1 hour before lunch and dinner); although most patients respond to this dose, if further therapeutic effect is desired and if tolerated, may gradually increase to 2.1 mg 1 hour before lunch and 4.2 mg 1 hour before dinner, and then (if needed) to 4.2 mg twice daily (1 hour before lunch and dinner). Maximum: 16.8 mg/day in 2 divided doses. In patients unable to tolerate 2.1 mg twice daily, consider 2.1 mg once daily (1 hour before dinner or at bedtime) to reduce the risk of CNS effects.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5db46910-62d8-4d0d-9939-9fd2f9829b40">Chemotherapy-induced nausea and vomiting, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, refractory</b>: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: 5 mg/m<sup>2</sup> administered 1 to 3 hours before chemotherapy, then administer 5 mg/m<sup>2</sup>/dose every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses/day; increase dose in increments of 2.5 mg/m<sup>2</sup> based on response and tolerability (maximum: 15 mg/m<sup>2</sup>/dose and 4 to 6 doses/day). Monitor for adverse reactions; consider reducing dose to 2.5 mg once daily 1 to 3 hours prior to chemotherapy to reduce the risk of CNS adverse reactions (manufacturer's labeling) <b>or</b> 2.5 to 10 mg 3 or 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18391612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18391612'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Initial: 4.2 mg/m<sup>2</sup> (rounded to the nearest 0.1 mg increment [or to the nearest 0.1 mL measurable increment on the calibrated oral dosing syringe]) 1 to 3 hours prior to chemotherapy and then every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses/day. Titrate dose in 2.1 mg/m<sup>2</sup> increments (during a cycle or in subsequent cycles) to clinical response. Maximum: 12.6 mg/m<sup>2</sup>/dose and 4 to 6 doses/day. In patients unable to tolerate 4.2 mg/m<sup>2</sup>, consider 2.1 mg/m<sup>2</sup> once daily 1 to 3 hours prior to chemotherapy to reduce the risk of CNS effects.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4991db68-3993-4d6b-906d-f3283c429f9f">Obstructive sleep apnea, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obstructive sleep apnea, moderate to severe (off-label use):</b>
<b>Oral:</b> 2.5 mg or 10 mg 1 hour before bedtime. An initial dose escalation is required for the 10 mg dose: Initiate at 2.5 mg 1 hour before bedtime for 7 days, followed by 5 mg 1 hour before bedtime for 7 days, and then 10 mg 1 hour before bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29121334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29121334'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990363"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987739"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F163473"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Central nervous system: Euphoria (antiemetic: 24%; appetite stimulant: 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial flushing (&gt;1%), palpitations (&gt;1%), tachycardia (&gt;1%), vasodilation (&gt;1%), flushing (≤1%), hypotension (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Abnormality in thinking (3% to 10%), dizziness (3% to 10%), drowsiness (3% to 10%), paranoia (3% to 10%), amnesia (&gt;1%), anxiety (&gt;1%), ataxia (&gt;1%), confusion (&gt;1%), depersonalization (&gt;1%), hallucination (&gt;1%), nervousness (&gt;1%), chills (≤1%), depression (≤1%), headache (≤1%), malaise (≤1%), nightmares (≤1%), speech disturbance (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3% to 10%), nausea (3% to 10%), vomiting (3% to 10%), anorexia (≤1%), diarrhea (≤1%), fecal incontinence (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (&gt;1%), myalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctival injection (≤1%), conjunctivitis (≤1%), visual disturbance (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (≤1%), rhinitis (≤1%), sinusitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Burning sensation of skin, delirium, disorientation, exacerbation of depression, falling, fatigue, insomnia, loss of consciousness, mental status changes (exacerbation of mania or schizophrenia), movement disorder, oral lesion, panic attack, pharyngeal edema, seizure, skin rash, swelling of lips, syncope, urticaria, visual disturbance</p></div>
<div class="block coi drugH1Div" id="F163488"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to dronabinol, sesame oil (capsules), alcohol (oral solution) or any component of the formulation; receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days (oral solution).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F163470"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: May cause occasional hypotension, possible hypertension, syncope, or tachycardia; patients with cardiac disorders may be at higher risk for hemodynamic instability. Avoid concomitant use with other medications associated with similar cardiovascular adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS adverse effects: Dronabinol has been reported to exacerbate depression, mania, or schizophrenia; screen patients for history of these conditions prior to treatment initiation. Significant CNS symptoms were associated with doses of 0.4 mg/kg in antiemetic studies. Avoid use in patients with a psychiatric history; if use cannot be avoided, monitor for new or worsening psychiatric symptoms. Avoid concomitant use with other medications associated with similar psychiatric adverse effects. May cause cognitive impairment, altered mental state, or CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). Older adult and pediatric patients may be more sensitive to neurologic and psychiatric effects of dronabinol.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: New or worsening paradoxical nausea, vomiting, and/or abdominal pain may occur with synthetic cannabinoids; may be severe. Symptoms are similar to cannabinoid hyperemesis syndrome, which is a cyclical syndrome with the same symptoms occurring with long-term use of cannabinoid products.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including disseminated rash, hives, lip swelling, oral lesions, skin burning, flushing, and throat tightness, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Dronabinol has been associated with seizures and seizure-like activity. Assess potential risks versus benefits in patient with a history of seizure disorder, those receiving antiseizure medications, or with other factors that may lower the seizure threshold.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Substance abuse: Patients with a history of substance abuse (including marijuana or alcohol abuse) or dependence may be likely to also abuse dronabinol. Assess risk for abuse or misuse prior to treatment and monitor patients with a history of substance abuse throughout treatment. Tolerance, psychological, and physical dependence may occur with prolonged use. EEG changes consistent with withdrawal have been reported upon abrupt dechallenge of dronabinol. Sleep disturbances have been observed for several weeks after discontinuing treatment with high dronabinol doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Concurrent drug therapy issues</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Disulfiram reaction: Dronabinol oral solution contains dehydrated alcohol, which may cause a disulfiram-like reaction (abdominal cramps, nausea, vomiting, headache, and flushing) in patients receiving disulfiram or other medications associated with this reaction (eg, metronidazole). Medications containing disulfiram or metronidazole should be discontinued at least 14 days prior to initiation of dronabinol oral solution and do not administer until 7 days following completion of dronabinol oral solution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C9 polymorphism: Clearance may be reduced and systemic effects increased in patients with CYP2C9 genetic polymorphism. Monitor for increased adverse effects in patients known to carry genetic variants associated with diminished CYP2C9 function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Older adults may be more sensitive to the neurological, psychoactive, and postural hypotensive effects of dronabinol; use with caution and consider effects of concomitant medications and underlying disease states.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). Risk for propylene glycol toxicity is increased for patients with preexisting renal insufficiency or seizure disorders (Lim 2014). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: May cause withdrawal symptoms upon abrupt discontinuation. Transient physical manifestations of withdrawal observed within 12 to 24 hours following drug discontinuation include irritability, insomnia, restlessness, “hot flashes,” sweating, rhinorrhea, loose stools, hiccoughs, and anorexia.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878435"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Syndros oral liquid solution contains 50% (w/w) dehydrated alcohol and 5.5% (w/w) propylene glycol; ethanol competitively inhibits propylene glycol metabolism, which may lead to propylene glycol toxicity in neonates or individuals with impaired elimination. Pediatric patients may be more sensitive to CNS adverse effects.</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults, including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F163483"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marinol: 2.5 mg, 5 mg [DSC], 10 mg [DSC] [contains sesame oil]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Syndros: 5 mg/mL (30 mL) [contains alcohol, usp, methylparaben, polyethylene glycol (macrogol), propylene glycol, propylparaben]</p></div>
<div class="block geq drugH1Div" id="F163466"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F163490"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (droNABinol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $1.66 - $11.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.50 - $24.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $5.00 - $45.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Marinol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $13.89</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Syndros Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $46.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F163526"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Marinol: C-III; Syndros: C-II</p></div>
<div class="block admp drugH1Div" id="F52612645"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules: The first dose should be administered on an empty stomach at least 30 minutes prior to eating; subsequent doses within a chemotherapy cycle may be administered without regard to meals. Once a dose has been titrated, the timing of doses with regard to food in subsequent cycles should maintain consistency with prior cycles.</p></div>
<div class="block adm drugH1Div" id="F27750095"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Anorexia in patients with AIDS: </b>Administer twice-daily doses 1 hour before lunch and dinner; administer single doses 1 hour before dinner or at bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chemotherapy-induced nausea and vomiting (refractory):</b> Administer the first dose on an empty stomach at least 30 minutes before eating; subsequent doses may be administered without regard to meals, although once titrated, the timing of administration in relation to meals should be kept consistent for each chemotherapy cycle.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Always use the provided calibrated oral dosing syringe when administering to ensure dose is measured and administered accurately. If the prescribed dose is &gt;5 mg, the total dose will need to be divided and drawn up in 2 or more portions using the oral syringe. Administer orally directly from oral dosing syringe; immediately follow with a full glass of water (180 to 240 mL). May also be administered through silicone-based enteral feeding tubes that are size ≥14 French (eg, nasogastric [NG], gastrostomy tube [G-tube], percutaneous endoscopic gastrostomy tube [PEG-tube], and gastro-jejunostomy tube [GJ-tube]); do not use polyurethane tubing; after administration, flush feeding tube with 30 mL of water using a catheter-tip syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Anorexia in patients with AIDS:</b> Administer 1 hour before lunch and 1 hour before dinner initially; if persistent or severe CNS adverse effects occur, administering later in the day (1 hour before dinner or at bedtime) may reduce the frequency of CNS adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chemotherapy-induced nausea and vomiting (refractory):</b> The first dose should be administered on an empty stomach at least 30 minutes prior to eating; subsequent doses within a chemotherapy cycle may be administered without regard to meals. Once a dose has been titrated, the timing of doses with regard to food in subsequent cycles should maintain consistency with prior cycles.</p></div>
<div class="block sts drugH1Div" id="F163499"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Store in a cool environment between 8°C and 15°C (46°F and 59°F) or refrigerated; protect from freezing. Capsules should be stored in a well-closed container.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store in a refrigerator between 2°C and 8°C (36°F and 46°F); excursions permitted up to 25°C (77°F). The opened bottle may be stored at 25°C (77°F). Discard unused portion 42 days after first opening. Keep in original carton (keep calibrated dosing syringe in original carton, too).</p></div>
<div class="block usep drugH1Div" id="F53566607"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of nausea and vomiting secondary to cancer chemotherapy in patients who have not responded to conventional antiemetics; treatment of anorexia associated with weight loss in AIDS patients (Capsules, oral liquid: All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F163532"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DroNABinol may be confused with droPERidol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">To ensure accurate measuring and administration of dronabinol oral solution, always use the provided calibrated oral dosing syringe.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299237"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F163475"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): DroNABinol may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: DroNABinol may increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): DroNABinol may increase the serum concentration of CycloSPORINE (Systemic). Specifically, dronabinol may displace cyclosporine from its protein-binding sites, leading to an increased concentration of active, unbound drug. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of DroNABinol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of DroNABinol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of DroNABinol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DroNABinol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DroNABinol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of DroNABinol. Specifically, disulfiram may produce severe intolerance to the alcohol contained in the dronabinol oral solution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of DroNABinol. Specifically, metronidazole may produce severe intolerance to the alcohol contained in the dronabinol oral solution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the tachycardic effect of Cannabinoid-Containing Products. Blood pressure raising effects and drowsiness may also be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Cannabinoid-Containing Products may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F48979079"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: A high-fat (59 g of fat), high-calorie (~950 calories) meal resulted in a 2.9-fold increase in AUC and a 4-hour delay in the median time to peak.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: A high-fat meal (59 g of fat) or high-calorie meal (~950 calories) resulted in a 2.5-fold increase in AUC and a 5-hour delay in the median time to peak; food also decreased the C<sub>max</sub> by ~20%.</p></div>
<div class="block dic drugH1Div" id="F621844"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Capsules contain sesame oil.</p></div>
<div class="block pri drugH1Div" id="F13386485"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Dronabinol is synthetic delta-9-tetrahydrocannabinol (delta-9-THC); THC crosses the placenta following maternal use of marijuana (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28182367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28182367'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the use of synthetic cannabinoids during pregnancy are limited.</p>
<p style="text-indent:-2em;margin-left:2em;">Maternal use of cannabinoids may increase the risk of adverse fetal/neonatal outcomes including growth restriction, low birth weight, preterm birth, and stillbirth. Some dosage forms also contain a significant amount of alcohol, which is also associated with adverse fetal/neonatal outcomes including CNS abnormalities, behavioral disorders, and impaired intellectual development.</p></div>
<div class="block mopp drugH1Div" id="F53566594"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CNS effects, seizures, heart rate, blood pressure, and substance abuse behavioral profile.</p></div>
<div class="block pha drugH1Div" id="F163469"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dronabinol (synthetic delta-9-tetrahydrocannabinol [delta-9-THC]), an active cannabinoid and natural occurring component of <i>Cannabis sativa L.</i> (marijuana), activates cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>. Activation of the CB<sub>1</sub> receptor produces marijuana-like effects on psyche and circulation, whereas activation of the CB<sub>2</sub> receptor does not. Dronabinol has approximately equal affinity for the CB<sub>1</sub> and CB<sub>2</sub> receptors; however, efficacy is less at CB<sub>2</sub> receptors. Activation of the cannabinoid system with dronabinol causes psychological effects that can be divided into 4 groups: affective (euphoria and easy laughter); sensory (increased perception of external stimuli and of the person's own body); somatic (feeling of the body floating or sinking in the bed); and cognitive (distortion of time perception, memory lapses, difficulty in concentration). Most effects (eg, analgesia, appetite enhancement, muscle relaxation, hormonal actions) are mediated by central cannabinoid receptors (CB<sub>1</sub>), their distribution reflecting many of the medicinal benefits and adverse effects (Grotenhermen 2003).</p></div>
<div class="block phk drugH1Div" id="F163487"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~0.5 to 1 hour</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 4 to 6 hours (psychoactive effects); ≥24 hours (appetite stimulation)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: 90% to 95%; 10% to 20% of dose reaches systemic circulation</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~10 L/kg; dronabinol is highly lipophilic</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive first-pass hepatic primarily via microsomal hydroxylation to metabolites, some of which are active; 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) is the major active metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Biphasic: Alpha: 4 to 5 hours; Terminal: 25 to 36 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 0.5 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (50%, &lt;5% as unchanged drug); Urine (10% to 15%); dronabinol metabolites have been detected in the urine and feces &gt;5 weeks following a single dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038605"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Laxenol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ronabin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Marinol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Marinol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Marinol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Elevat</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29121334">
<a name="29121334"></a>Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE clinical trial: effects of dronabinol in obstructive sleep apnea. <i>Sleep</i>. 2018;41(1)zsx184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/29121334/pubmed" id="29121334" target="_blank">29121334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dronabinol.1">
<a name="Dronabinol.1"></a>Dronabinol [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals, Inc; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12956617">
<a name="12956617"></a>Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. <i>Paediatr Drugs.</i> 2003;5(9):597-613. doi:10.2165/00148581-200305090-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/12956617/pubmed" id="12956617" target="_blank">12956617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26960036">
<a name="26960036"></a>Flank J, Robinson PD, Holdsworth M, et al. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. <i>Pediatr Blood Cancer</i>. 2016;63(7):1144-1151. doi:10.1002/pbc.25955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/26960036/pubmed" id="26960036" target="_blank">26960036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grotenhermen.1">
<a name="Grotenhermen.1"></a>Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. <i>Clin Pharmacokinet</i>. 2003;42(2):327-360.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25762872">
<a name="25762872"></a>Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. <i>J Pediatr Pharmacol Ther</i>. 2014;19(4):277-282. doi:10.5863/1551-6776-19.4.277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/25762872/pubmed" id="25762872" target="_blank">25762872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18391612">
<a name="18391612"></a>Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/18391612/pubmed" id="18391612" target="_blank">18391612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marinol.1">
<a name="Marinol.1"></a>Marinol (dronabinol) [prescribing information]. High Point, NC: Patheon Softgels Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182367">
<a name="28182367"></a>National Academies of Sciences, Engineering, and Medicine (NASEM). <i>The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations for Research</i>. The National Academies Press; January 2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/28182367/pubmed" id="28182367" target="_blank">28182367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Orkin.1">
<a name="Orkin.1"></a>Orkin SH, Fisher DE, Look AT, et al., eds. <i>Oncology of Infancy and Childhood</i>. Philadelphia, PA: Saunders Elsevier; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678694">
<a name="32678694"></a>Rower JE, King AD, Wilkins D, et al. Dronabinol prescribing and exposure among children and young adults diagnosed with cancer. <i>J Adolesc Young Adult Oncol</i>. 2021;10(2):175-184. doi:10.1089/jayao.2020.0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/32678694/pubmed" id="32678694" target="_blank">32678694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Syndros.1">
<a name="Syndros.1"></a>Syndros (dronabinol) [prescribing information]. Round Rock, TX: Benuvia Therapeutics LLD; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11440936">
<a name="11440936"></a>Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. <i>BMJ</i>. 2001;323(7303):16-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/11440936/pubmed" id="11440936" target="_blank">11440936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ullrich.1">
<a name="Ullrich.1"></a>Ullrich C, Duncan J, Joselow M, Wolfe J. Pediatric palliative care. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 7.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dronabinol-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13256 Version 294.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
